Telehealth Ketamine in Indiana: Access, Laws, and What to Know

Telehealth ketamine in Indiana is legal and available in 2026. State law lets providers start care through a real-time audio-visual evaluation rather than requiring an initial in-person exam, though the visit must meet the same standard of care as an office visit. Ketamine is classified as a Schedule III controlled substance under the federal Controlled Substances Act, a category for drugs with accepted medical use and a moderate potential for abuse or dependence. Prescribing is governed jointly by the Indiana Medical Licensing Board, a division of the Indiana Professional Licensing Agency (PLA), and federal Drug Enforcement Administration rules under the Ryan Haight Online Pharmacy Consumer Protection Act. Indiana also requires prescribers to check the state's INSPECT prescription drug monitoring program before writing a controlled substance prescription. Because federal telehealth rules for controlled substances are still being finalized, confirm current requirements with your provider and the Indiana Medical Licensing Board before starting treatment.

Yes. Indiana Code Title 25 and the Indiana Medical Licensing Board, a division of the Indiana Professional Licensing Agency, permit providers to establish a patient-provider relationship through telehealth, including real-time audio-visual visits. Indiana enacted Senate Enrolled Act 3 in 2016 and later legislation to set telehealth practice standards, and the state does not impose a blanket rule requiring an initial in-person exam before telehealth prescribing. Providers must still complete what the state calls an adequate evaluation and meet the same standard of care expected in an in-person visit, which typically includes a full psychiatric history, current medication review, and risk assessment.

Because ketamine is a Schedule III controlled substance, prescribers must also follow federal rules under the DEA Diversion Control Division, including the Ryan Haight Online Pharmacy Consumer Protection Act, the federal law that generally requires an in-person medical evaluation before prescribing controlled substances online, subject to specific exceptions. Temporary flexibilities first extended during the COVID-19 public health emergency have allowed many controlled substance telehealth evaluations to proceed without a prior in-person visit, and the DEA has continued to extend these flexibilities while it finalizes permanent telemedicine regulations. Because both layers of rules can shift, verify current requirements with the Indiana Medical Licensing Board or read our telehealth legality overview before scheduling an appointment.

Indiana's prescription drug monitoring program, INSPECT (Indiana Scheduled Prescription Electronic Collection and Tracking), is operated by the Indiana Board of Pharmacy, and providers must query it before prescribing a controlled substance like ketamine. INSPECT is one of the more actively used PDMPs in the Midwest, and the Indiana Medical Licensing Board investigates prescribing concerns tied to its data. Providers offering telehealth ketamine in Indiana must hold an active Indiana medical license and a valid DEA registration, and are expected to document the clinical basis for treatment the same way an in-person prescriber would.

Patients can confirm a prescriber's license status through the Indiana Professional Licensing Agency. If you live near the Kentucky border and split time between the two states, review our Kentucky telehealth ketamine guide to understand which state's rules apply during your appointment. For a broader look at how these rules compare nationally, see our state telehealth regulations guide.

Provider availability for telehealth ketamine in Indiana is moderate. According to U.S. Census Bureau estimates, Indiana's population is approximately 6.8 million, centered on the Indianapolis metro area, home to about 2.1 million residents, with secondary population centers in Fort Wayne, Evansville, South Bend, and the Gary and Northwest Indiana corridor near Chicago. Several national telehealth ketamine platforms accept Indiana patients. Indiana also participates in the Interstate Medical Licensure Compact, an agreement among member states that streamlines medical licensing for physicians who want to practice in more than one state, which helps expand the pool of available prescribers.

Psychiatric and mental health provider shortages persist in parts of the state, particularly in rural southern, central, and eastern Indiana, where the nearest psychiatrist or in-person ketamine clinic can be an hour or more away. Telehealth closes much of that gap by letting patients complete evaluations and follow-up visits from home. Before choosing a provider, compare credentials, evaluation process, and pricing; our guide to choosing a ketamine provider walks through what to look for.

Compounding pharmacies can ship ketamine formulations to Indiana patients without unusual barriers. The Indiana Board of Pharmacy regulates nonresident pharmacy operations under Indiana Administrative Code Title 856, and any out-of-state compounding pharmacy must register as a nonresident pharmacy before shipping to Indiana addresses. Indiana's central Midwest location generally means shorter shipping times from major compounding hubs, typically 2-3 business days.

The Indiana Board of Pharmacy enforces standards set by the U.S. Pharmacopeia (USP), a nonprofit organization that sets quality and sterility standards for compounded medications, and maintains a public database of licensed pharmacies. Before filling a prescription, confirm that your compounding pharmacy is properly registered in Indiana.

Indiana has telehealth parity provisions that require commercial insurers to cover telehealth visits, though the exact scope has changed through several legislative updates. Parity generally applies to the visit itself, not to whether a specific medication is covered. Off-label compounded ketamine for psychiatric use is generally not covered by private insurance in Indiana, regardless of parity rules. Spravato (esketamine), the FDA-approved nasal spray formulation of ketamine therapy, is more likely to be covered by commercial insurance and by Indiana Medicaid with prior authorization when a patient meets criteria for treatment-resistant depression.

Indiana Medicaid, delivered through Indiana Health Coverage Programs including Hoosier Healthwise and the Healthy Indiana Plan, does not cover compounded ketamine for mental health conditions. Because a meaningful share of Indiana residents rely on these programs, cost remains a real barrier for some patients. Monthly costs for telehealth ketamine care in Indiana tend to run moderate compared to coastal states: medication typically costs $150-$300 per month and consultation fees run $100-$200. HSA and FSA funds may apply to eligible expenses; check with your benefits administrator. For a full national breakdown, see our insurance versus cash-pay comparison.